Tagged oliggonucleotides and their use in nucleic acid amplification methods
Abstract
The present invention relates to a method for the selective amplification of at least one target nucleic acid sequence from a nucleic acid sample, said method comprising the steps of (a) treating a nucleic acid sample comprising a target nucleic acid sequence with a tagged oligonucleotide comprising first and second regions, said first region comprising a target hybridizing sequence which hybridizes to a 3'-end of said target nucleic acid sequence and said second region comprising a tag sequence situated 5' to said target hybridizing sequence, wherein said second region does not stably hybridize to a target nucleic acid containing said target nucleic acid sequence; (b)reducing in said nucleic acid sample the effective concentration of unhybridized tagged oligonucleotide having an active form in which a target hybridizing sequence of said unhybridized tagged oligonucleotide is available for hybridization to said target nucleic acid sequence; and (c) producing amplification products in a nucleic acid amplification reaction using first and second oligonucleotides, wherein said first oligonucleotide comprises a hybridizing sequence which hybridizes to a 3'-end of the complement of said target nucleic acid sequence and said second oligonucleotide comprises a hybridizing sequence which hybridizes to the complement of said tag sequence, wherein said second oligonucleotide does stably hybridize to a target nucleic acid containing said target nucleic acid sequence, wherein each of said amplification products comprises a base sequence which is substantially identical or complementary to the base sequence of said target nucleic acid sequence and further comprises a base sequence which is substantially identical or complementary to all or a portion of said tag sequence, and wherein step (b) comprises inactivating unhybridized tagged oligonucleotide so that said unhybridized tagged oligonucleotide does not stably hybridize to said target nucleic acid sequence during step (c).

Term
0.7 yearsto projected expiry
Projected expiry 6 June 2027, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP1598429A1 | Cites | European Patent Office (EPO) | A | Search report |
| US2002025525A1 | Cites | United States of America | A | Search report |
| WO9115601A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report |
| NITSCHE A ET AL: "Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 45, no. 11, 1 November 1999 (1999-11-01), pages 1932 - 1937, XP002966634, ISSN: 0009-9147 | Non-patent | – | – | Search report |
| DIDENKO V V: "DNA PROBES USING FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET): DESIGNS AND APPLICATIONS", BIOTECHNIQUES, INFORMA LIFE SCIENCES PUBLISHING, WESTBOROUGH, MA, US, vol. 31, no. 5, 1 November 2001 (2001-11-01), pages 1106 - 1121, XP001082961, ISSN: 0736-6205 | Non-patent | – | – | Search report |
| SHULDINER A R ET AL: "RNA TEMPLATE-SPECIFIC POLYMERASE CHAIN REACTION (RS-PCR): A NOVEL STRATEGY TO REDUCE DRAMATICALLY FALSE POSITIVES", GENE, ELSEVIER, AMSTERDAM, NL, vol. 91, no. 1, 1990, pages 139 - 142, XP001153862, ISSN: 0378-1119 | Non-patent | – | – | Search report |
40 members in 11 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 811581P | United States of America | – | |
| 81158106 | United States of America | P | |
| 871442P | United States of America | – | |
| 87144206 | United States of America | P | |
| 07795916 | European Patent Office (EPO) | A |
Members40
| Document | Office | Kind | |
|---|---|---|---|
| US2007281317A1 | United States of America | A1 | |
| AU2007258455A1 | Australia | A1 | |
| CA2659543A1 | Canada | A1 | |
| WO2007146154A1 | World Intellectual Property Organization (WIPO) | A1 | |
| EP1945821A1 | European Patent Office (EPO) | A1 | |
| EP2017356A2 | European Patent Office (EPO) | A2 | |
| EP2017356A3This record | European Patent Office (EPO) | A3 | |
| EP2017356A8 | European Patent Office (EPO) | A8 | |
| JP2009539379A | Japan | A | |
| US7833716B2 | United States of America | B2 | |
| EP1945821B1 | European Patent Office (EPO) | B1 | |
| US2011014623A1 | United States of America | A1 | |
| AT496144T | Austria | T | |
| ATE496144T1 | Austria | T1 | |
| DE602007012045D1 | Germany | D1 | |
| DK1945821T3 | Denmark | T3 | |
| ES2358296T3 | Spain | T3 | |
| EP2345740A1 | European Patent Office (EPO) | A1 | |
| US8034570B2 | United States of America | B2 | |
| EP2017356B1 | European Patent Office (EPO) | B1 | |
| AT536424T | Austria | T | |
| ATE536424T1 | Austria | T1 | |
| US2012003651A1 | United States of America | A1 | |
| DK2017356T3 | Denmark | T3 | |
| PL2017356T3 | Poland | T3 | |
| US8278052B2 | United States of America | B2 | |
| US2013029344A1 | United States of America | A1 | |
| JP2013027408A | Japan | A | |
| JP5152929B2 | Japan | B2 | |
| AU2007258455B2 | Australia | B2 | |
| US8580510B2 | United States of America | B2 | |
| US2014066330A1 | United States of America | A1 | |
| JP5680606B2 | Japan | B2 | |
| EP2345740B1 | European Patent Office (EPO) | B1 | |
| CA2659543C | Canada | C | |
| US9284549B2 | United States of America | B2 | |
| US2016186249A1 | United States of America | A1 | |
| US10167500B2 | United States of America | B2 | |
| US2019024158A9 | United States of America | A9 | |
| USRE48909E | United States of America | E |
84 legal events, as 10 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Opt-out of the competence of the unified patent court (upc) registeredP01 | P01 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| European patent discontinued in the territory of the republic of polandLAPE | LAPE | PL | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed because of non-payment of the annual feeLapsedV1 | V1 | NL | |
| Ep patent lapsedLapsedEBP | EBP | DK | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097 | R097 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05 | MK05 | AT | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lt: invalidation of european patent or patent extensionLTIE | LTIE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Translation of ep patentT3 | T3 | PL | |
| Dpma publication of mentioned ep patent grantGrantedR096 | R096 | DE | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Translation filed for an european patent granted for nl, confirming art. 52 par. 1 or 6 of the patents act 1995GrantedT3 | T3 | NL | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Designation fees paidAKX | AKX | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Request for examination filed17P | 17P | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 2017356
- Application
- 80057318
Titles3
- German
- Markierte Oligonukleotide und ihre Verwendung in Nukleinsäureverstärkungsverfahren
- English
- Tagged oliggonucleotides and their use in nucleic acid amplification methods
- French
- Oligonucléotides marqués et leur utilisation dans des procédés d'amplification d'acide nucléique
Classification
- CPC, 3
- C12Q1/6853
- C12Q1/6848
- C12Q1/6865
- IPC, 1
- C12Q1 68
Designated states32
- Contracting states, 32
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
- Monaco
- Malta
and 8 moreShow fewer
- Netherlands (Kingdom of the)
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye